Clinical review report: Tildrakizumab (Ilumya) (Sun Pharma Global FZE) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tildrakizumab 100 mg/mL for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
August 2021, 2021
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of tildrakizumab 100 mg/mL for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |
|---|---|
| Physical Description: | 1 PDF file (123 pages) illustrations |